Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study
Abstract Background Human papillomavirus (HPV)-associated cancers are vaccine preventable. In 2016, the previously recommended three-dose HPV vaccination series was changed to a two-dose series and nine-valent HPV vaccine (9vHPV) became the only HPV vaccine available in the United States. Data on lo...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-025-10961-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850042965345435648 |
|---|---|
| author | Jonathan Steinberg Gitika Panicker Elizabeth R. Unger Ian Blake Rayleen M. Lewis Jesse Geis Dana Bruden Marc Fischer Lauri E. Markowitz Michael G. Bruce |
| author_facet | Jonathan Steinberg Gitika Panicker Elizabeth R. Unger Ian Blake Rayleen M. Lewis Jesse Geis Dana Bruden Marc Fischer Lauri E. Markowitz Michael G. Bruce |
| author_sort | Jonathan Steinberg |
| collection | DOAJ |
| description | Abstract Background Human papillomavirus (HPV)-associated cancers are vaccine preventable. In 2016, the previously recommended three-dose HPV vaccination series was changed to a two-dose series and nine-valent HPV vaccine (9vHPV) became the only HPV vaccine available in the United States. Data on longer-term duration of antibodies following a 9vHPV two-dose series are limited. We evaluated the immunogenicity and duration of antibodies up to three years after vaccination with a two-dose series of 9vHPV in a cohort of Alaska Native children. Methods We enrolled Alaska Native children aged 9–14 years who received 9vHPV in Anchorage, Alaska during 2017–2018. We collected sera at six months after dose one and at one month, one year, and three years after dose two to measure type-specific immunoglobulin G (IgG) concentrations for the 9vHPV types (HPV6/11/16/18/31/33/45/52/58). Aggregate type-specific IgG concentrations were reported as geometric mean concentrations (GMC). Results A total of 227 children completed the two-dose series of 9vHPV and provided ≥ 1 blood sample. The median age at enrollment was 11.0 years (range: 9.0–14.6) and was similar between males and females (p = 0.11). At one month after dose two, all 197 participants with available serum were seropositive for all 9vHPV types. Among 145 participants who had a specimen available at three years after dose two, 134 (92%) remained seropositive for all 9vHPV types. GMC peaked for all types at one month post dose two and remained higher at three years post dose two compared to six months post dose one. Conclusions We found high immunogenicity and antibody persistence after a two-dose series of 9vHPV in this cohort of Alaska Native children. Further follow-up will determine duration of antibody detection in this cohort. |
| format | Article |
| id | doaj-art-89f1c6a8ddb248dbaa335c71ba863c30 |
| institution | DOAJ |
| issn | 1471-2334 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj-art-89f1c6a8ddb248dbaa335c71ba863c302025-08-20T02:55:21ZengBMCBMC Infectious Diseases1471-23342025-04-012511810.1186/s12879-025-10961-zImmunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort studyJonathan Steinberg0Gitika Panicker1Elizabeth R. Unger2Ian Blake3Rayleen M. Lewis4Jesse Geis5Dana Bruden6Marc Fischer7Lauri E. Markowitz8Michael G. Bruce9Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and PreventionDivision of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and PreventionDivision of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and PreventionArctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and PreventionDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and PreventionArctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and PreventionArctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and PreventionArctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and PreventionDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and PreventionArctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and PreventionAbstract Background Human papillomavirus (HPV)-associated cancers are vaccine preventable. In 2016, the previously recommended three-dose HPV vaccination series was changed to a two-dose series and nine-valent HPV vaccine (9vHPV) became the only HPV vaccine available in the United States. Data on longer-term duration of antibodies following a 9vHPV two-dose series are limited. We evaluated the immunogenicity and duration of antibodies up to three years after vaccination with a two-dose series of 9vHPV in a cohort of Alaska Native children. Methods We enrolled Alaska Native children aged 9–14 years who received 9vHPV in Anchorage, Alaska during 2017–2018. We collected sera at six months after dose one and at one month, one year, and three years after dose two to measure type-specific immunoglobulin G (IgG) concentrations for the 9vHPV types (HPV6/11/16/18/31/33/45/52/58). Aggregate type-specific IgG concentrations were reported as geometric mean concentrations (GMC). Results A total of 227 children completed the two-dose series of 9vHPV and provided ≥ 1 blood sample. The median age at enrollment was 11.0 years (range: 9.0–14.6) and was similar between males and females (p = 0.11). At one month after dose two, all 197 participants with available serum were seropositive for all 9vHPV types. Among 145 participants who had a specimen available at three years after dose two, 134 (92%) remained seropositive for all 9vHPV types. GMC peaked for all types at one month post dose two and remained higher at three years post dose two compared to six months post dose one. Conclusions We found high immunogenicity and antibody persistence after a two-dose series of 9vHPV in this cohort of Alaska Native children. Further follow-up will determine duration of antibody detection in this cohort.https://doi.org/10.1186/s12879-025-10961-zHuman papillomavirus virusesVaccinesAlaska |
| spellingShingle | Jonathan Steinberg Gitika Panicker Elizabeth R. Unger Ian Blake Rayleen M. Lewis Jesse Geis Dana Bruden Marc Fischer Lauri E. Markowitz Michael G. Bruce Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study BMC Infectious Diseases Human papillomavirus viruses Vaccines Alaska |
| title | Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study |
| title_full | Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study |
| title_fullStr | Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study |
| title_full_unstemmed | Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study |
| title_short | Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study |
| title_sort | immunogenicity and duration of antibodies after vaccination with a two dose series of the nine valent human papillomavirus vaccine among alaska native children a prospective cohort study |
| topic | Human papillomavirus viruses Vaccines Alaska |
| url | https://doi.org/10.1186/s12879-025-10961-z |
| work_keys_str_mv | AT jonathansteinberg immunogenicityanddurationofantibodiesaftervaccinationwithatwodoseseriesoftheninevalenthumanpapillomavirusvaccineamongalaskanativechildrenaprospectivecohortstudy AT gitikapanicker immunogenicityanddurationofantibodiesaftervaccinationwithatwodoseseriesoftheninevalenthumanpapillomavirusvaccineamongalaskanativechildrenaprospectivecohortstudy AT elizabethrunger immunogenicityanddurationofantibodiesaftervaccinationwithatwodoseseriesoftheninevalenthumanpapillomavirusvaccineamongalaskanativechildrenaprospectivecohortstudy AT ianblake immunogenicityanddurationofantibodiesaftervaccinationwithatwodoseseriesoftheninevalenthumanpapillomavirusvaccineamongalaskanativechildrenaprospectivecohortstudy AT rayleenmlewis immunogenicityanddurationofantibodiesaftervaccinationwithatwodoseseriesoftheninevalenthumanpapillomavirusvaccineamongalaskanativechildrenaprospectivecohortstudy AT jessegeis immunogenicityanddurationofantibodiesaftervaccinationwithatwodoseseriesoftheninevalenthumanpapillomavirusvaccineamongalaskanativechildrenaprospectivecohortstudy AT danabruden immunogenicityanddurationofantibodiesaftervaccinationwithatwodoseseriesoftheninevalenthumanpapillomavirusvaccineamongalaskanativechildrenaprospectivecohortstudy AT marcfischer immunogenicityanddurationofantibodiesaftervaccinationwithatwodoseseriesoftheninevalenthumanpapillomavirusvaccineamongalaskanativechildrenaprospectivecohortstudy AT lauriemarkowitz immunogenicityanddurationofantibodiesaftervaccinationwithatwodoseseriesoftheninevalenthumanpapillomavirusvaccineamongalaskanativechildrenaprospectivecohortstudy AT michaelgbruce immunogenicityanddurationofantibodiesaftervaccinationwithatwodoseseriesoftheninevalenthumanpapillomavirusvaccineamongalaskanativechildrenaprospectivecohortstudy |